FindTrial
Sign In

anti-BCMA CAR-T

BIOLOGICAL8 trials

Sponsors

Xinqiao Hospital of Chongqing, Second Affiliated Hospital, School of Medicine, Zhejiang University, Institute of Hematology & Blood Diseases Hospital, China

Conditions

Multiple MyelomaPlasma Cell LeukemiaRelapsed or Refractory Multiple Myeloma

Early Phase 1

Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma
NCT04637269
Xinqiao Hospital of ChongqingMultiple Myeloma
Start: 2020-11-17End: 2023-11-01Target: 16Updated: 2020-11-19

Phase 1

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma
NCT04706936
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityRelapsed or Refractory Multiple Myeloma
Start: 2021-04-01End: 2024-04-30Target: 25Updated: 2023-02-06

Phase 2

BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT
RecruitingNCT05846737
Institute of Hematology & Blood Diseases Hospital, ChinaMultiple Myeloma
Start: 2023-05-29End: 2028-05-01Target: 20Updated: 2024-07-25
A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities
RecruitingNCT05850286
Institute of Hematology & Blood Diseases Hospital, ChinaMultiple Myeloma
Start: 2023-04-21End: 2027-04-30Target: 20Updated: 2025-08-04
A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma
Active, not recruitingNCT05860036
Institute of Hematology & Blood Diseases Hospital, ChinaMultiple Myeloma
Start: 2023-04-04End: 2028-03-10Target: 40Updated: 2025-08-03
A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia
RecruitingNCT05870917
Institute of Hematology & Blood Diseases Hospital, ChinaPlasma Cell Leukemia
Start: 2023-04-25End: 2027-04-01Target: 20Updated: 2026-03-02
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia
RecruitingNCT05979363
Institute of Hematology & Blood Diseases Hospital, ChinaPlasma Cell Leukemia
Start: 2023-08-14End: 2028-07-01Target: 20Updated: 2025-08-03
BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
RecruitingNCT06793449
Institute of Hematology & Blood Diseases Hospital, ChinaMultiple Myeloma
Start: 2025-02-05End: 2030-12-31Target: 80Updated: 2025-08-03

Related Papers

Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).
2026-02-27
BCMA CAR T-cell therapy in newly diagnosed primary plasma cell leukemia ineligible for transplantation: An open label, single-arm, phase 2 study (CAREMM-002)
Blood2025-11-03
CAC-MM-001: Anti-BCMA CAR-T therapy followed by autologous stem cell transplantation and second CAR-T (CART-ASCT-CART2) in newly diagnosed multiple myeloma patients with P53 gene abnormalities.
Blood2025-11-03
CART–ASCT–CART2 sandwich regimen as frontline therapy: A phase II trial in patients with primary plasma cell leukemia
Blood2025-11-03
BCMA CAR T-cell therapy in newly diagnosed transplant-ineligible multiple myeloma: An open label, single-arm, phase 2 study (CAREMM-001)
Blood2025-11-03
BCMA CAR-T Therapy As First-Line Consolidation Treatment in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: An Open Label, Single-Arm, Phase 2 Study (CAREMM-001)
Blood2024-11-053 citations
A Phase 2 Study of CART-ASCT-CART2 Sandwich Regimen Treatment in Patients with Primary Plasma Cell Leukemia
Blood2024-11-052 citations
CAC-MM-001: A B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Followed By Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities
Blood2024-11-05
CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
Cancer Immunology Research2024-10-213 citations
CD27-Armored BCMA-CAR T Cell (CBG-002) Therapy for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
Blood2023-11-024 citations